Lytix Biopharma has appointed Stephen Worsley as its Chief Business Officer


Oslo, NorwayAnd the 5 September 2022 /PRNewswire/– Lytix Biopharma (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company, has announced the appointment of Stephen Worsley As Chief Business Officer (CBO).

Stephen Worsley He is a pharmaceutical executive with over 25 years of experience leading business development in increasingly impactful roles and in executing high-value strategic deals in the biopharmaceutical market and drug discovery/development. As a business development executive, Worsley has led negotiations on transformative, award-winning technology and product partnerships for leading treatment companies.

The latest developments Stephen Worsley He served as Vice President of Strategic Business Development at Redwood Biosciences / Catalent Pharma Services. Prior to that, he held the position of CBO at Sutro Biopharma, Senior Vice President of Business Development at IndiMolecular and Vice President of Business Development at Peregrine Pharmaceutical (dba Avid Pharma Services) among other roles in his career.

As we plan to continually progress to reach many important milestones in our development programs at Lytix, we are pleased to welcome Stephen Worsley For our management team at Lytix Biopharma”, says Øystein Rekdal, CEO of Lytix. “His extensive experience in business development where he has led several strategic partnerships, acquisitions, equity investments, clinical collaborations, and external licensing transactions will play a key role as we grow our exciting pipeline of cancer immunostimulants through further clinical development and towards the market, with many partnership opportunities potential along the way.”

Stephen will enter his lead position at Lytix in September 6. With the CBO position, he will join Lytix’s executive management team.

I am very pleased to join the Lytix team at an exciting time for the company as we are developing a very promising new class of immunostimulant drugs for the treatment of cancer.” He said Stephen Worsley. “There is a growing interest in the platform and cutting-edge clinical outcomes that will allow Lytix to consider many of the values ​​that create business development opportunities in the coming months and years.. “

For more information please contact:
Ole Peter NordbyAnd the [email protected]

This information was brought to you by Cision http://news.cision.com

Source: Lytix Biopharma AS



Source link

Leave a Comment